Bartłomiej Żerek

Title: Bartłomiej Żerek: Innovator in Anticancer Research

Introduction

Bartłomiej Żerek is a notable inventor based in Dąbrowa, Poland. He has made significant contributions to the field of cancer treatment through his innovative research and development of fusion proteins. His work focuses on creating solutions that can potentially improve the lives of those affected by cancer.

Latest Patents

Bartłomiej Żerek holds a patent for an anticancer fusion protein comprising TRAIL and interferon. This fusion protein includes domain (a), which is a functional fragment of the hTRAIL protein sequence, starting with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment with at least 70% sequence identity. Additionally, domain (b) consists of a sequence of an immunostimulating effector peptide, which is attached at either the C-terminus or N-terminus of domain (a). This innovative fusion protein has the potential to be used in the treatment of various cancer diseases.

Career Highlights

Bartłomiej Żerek is currently associated with Adamed Sp. z o.o., where he continues to advance his research in the field of oncology. His dedication to developing effective cancer treatments showcases his commitment to improving patient outcomes.

Collaborations

He collaborates with esteemed colleagues, including Jerzy Szczepan Pieczykolan and Krzysztof Kazimierz Lemke. Their combined expertise contributes to the innovative projects they undertake in the realm of cancer research.

Conclusion

Bartłomiej Żerek's work in developing anticancer fusion proteins represents a significant advancement in cancer treatment. His innovative approach and collaboration with fellow researchers highlight the importance of teamwork in scientific discovery.